Model‐Based Meta‐Analysis for Multiple Myeloma: A Quantitative Drug‐Independent Framework for Efficient Decisions in Oncology Drug Development

The failure rate for phase III trials in oncology is high; quantitative predictive approaches are needed. We developed a model‐based meta‐analysis (MBMA) framework to predict progression‐free survival (PFS) from overall response rates (ORR) in relapsed/refractory multiple myeloma (RRMM), using data...

Descripción completa

Detalles Bibliográficos
Autores principales: Teng, Zhaoyang, Gupta, Neeraj, Hua, Zhaowei, Liu, Guohui, Samnotra, Vivek, Venkatakrishnan, Karthik, Labotka, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867027/
https://www.ncbi.nlm.nih.gov/pubmed/29168990
http://dx.doi.org/10.1111/cts.12524

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867027/
https://www.ncbi.nlm.nih.gov/pubmed/29168990
http://dx.doi.org/10.1111/cts.12524

Ejemplares similares